胰岛素样生长因子1受体在甲状腺相关眼病中的作用

The role of insulin-like growth factor 1 receptor in thyroid associated ophthalmopathy

甲状腺相关眼病发病机制尚未完全阐明.胰岛素样生长因子1受体(insulin-like growth factor 1,IGF-1R)的过度表达在甲状腺相关性眼病的发病中具有一定促进作用,其抑制剂替妥木单抗的应用会对甲状腺相关眼病的临床表现及发病过程产生抑制作用.而甲状腺相关眼病患者血清中免疫球蛋白G的升高及β-阻滞蛋白的升高可调节IGF-1R的表达或作用都会对甲状腺相关眼病的临床表现及发病过程产生促进作用.2020年,替妥木单抗成为首个获得美国FDA批准的治疗TAO的药物后,靶向抗IGF-1R治疗和相关临床试验的实施,为研究IGF-1R在TAO发病中的作用与TAO的靶向治疗奠定了基础.

The pathogenic mechanisms of thyroid-associated ophthalmopathy(TAO)have not been fully elucidated.Overexpression of insulin-like growth factor 1 receptor(IGF-1R)plays a certain promoting role in the pathogenesis of TAO,and the use of its inhibitor,teprotumumab,can exert an inhibitory effect on the clinical manifestations and progression of TAO.Elevated levels of immunoglobulin G and beta-blocking protein in the serum of TAO patients can regulate the expression or function of IGF-1R,promoting the clinical manifestations and progression of TAO.In 2020,teprotumumab became the first drug approved by the U.S.FDA for the treatment of TAO,and the implementation of targeted anti-IGF-1R therapy and related clinical trials have laid the foundation for studying the role of IGF-1R in the pathogenesis of TAO and targeted therapy for TAO.